Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753275 | 0.84 | HSD17B3 (0.37) | GRM5HDAC2 | |
| SCHEMBL27621253 | 0.83 | NR1H2 (0.46) | GRM5NR1H2GPR119CRBNESR2 | |
| SCHEMBL6391453 | 0.83 | GPR119 (0.47) | GRM5USP30GPR119CRBNPTPN2 | |
| Iodide SCHEMBL6394307 | 0.82 | GPR119 (0.46) | GRM5USP30GPR119CRBNPTPN2 | |
| SCHEMBL12053473 | 0.82 | GRM5 (0.43) | GRM5NR1H2USP30GPR119CRBN | |
| SCHEMBL1363015 | 0.81 | GRM5 (0.48) | GRM5USP30GPR119CRBNESR2 | |
| SCHEMBL27233567 | 0.81 | NR1H2 (0.53) | GRM5NR1H2GPR119ESR2PARP14 | |
| SCHEMBL1009267 | 0.81 | ESR2 (0.53) | GRM5NR1H2GPR119ESR2PARP14 | |
| SCHEMBL27233616 | 0.80 | RET (0.49) | GRM5USP30GPR119 | |
| SCHEMBL27233612 | 0.80 | GPR119 (0.48) | GRM5USP30GPR119CRBNKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | GRM5 802/4885NR1H2 219/4885USP30 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.